Prostate Cancer Prevention with 5 Alpha-Reductase Inhibitors-Reference-Cited by-同舟云学术

Prostate Cancer Prevention with 5 Alpha-Reductase Inhibitors

Published:2010 Issue: Volume: Page:109-114
ISSN:0080-0015
Container-title:Clinical Cancer Prevention
language:
Short-container-title:

Author:

Parekh Dipen J.

Publisher

Springer Berlin Heidelberg

Link

http://link.springer.com/content/pdf/10.1007/978-3-642-10858-7_9

Reference25 articles.

1. Andriole G, Bostwick D, Brawley O et al (2004) Chemoprevention of prostate cancer in men at high risk: rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. J Urol 172(4 Pt 1):1314–1317

2. Andriole GL, Humphrey PA, Serfling RJ, Grubb RL (2007) High-grade prostate cancer in the Prostate Cancer Prevention trial: fact or artifact? J Natl Cancer Inst 99:1355–1356

3. Ankerst DP, Thompson IM (2006) Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification. Arch Ital Urol Androl 78:125–129

4. Clark RV, Hermann DJ, Cunningham GR et al (2004) Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5 alpha-reductase inhibitor. J Clin Endocrinol Metab 89:2179–2184

5. Cohen YC, Liu KS, Heyden NL et al (2007) Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention trial. J Natl Cancer Inst 99:1366–1374, Patients treated with finasteride had a significantly smaller prostate volume resulting in a disproportionate sampling of the tumor during biopsy, allowing for increased identification of high-grade tumor

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 5α-reductase 1 mRNA levels are positively correlated with TRAMP mouse prostate most severe lesion scores;PLOS ONE;2017-05-11

2. Prevention of Prostate Cancer;Fundamentals of Cancer Prevention;2013-09-12

3. A Population-Based Nested Case-Control Study in Taiwan: Use of 5α-Reductase Inhibitors Did Not Decrease Prostate Cancer Risk in Patients with Benign Prostate Hyperplasia;The Oncologist;2012-06-20